ACTRN12611000982910已完成未知
A randomised controlled trial evaluating the impact of the new Supported Transfer & Accelerated Rehabilitation Team (START) on hospital length of stay, subsequent hospitalisations, institutionalisation and cost in patients being discharged from hospital in the Waikato region who have recently suffered an acute illness or injury.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 65 Years 至 100 No limit(—)
- 性别
- All
入选标准
- •1. The client is over 65 years (or close in age and interest) and lives within the catchment area Waikato DHB; 2. The client does not require acute hospital based treatment; 3. The client consents to being treated at home by the team, is aware of and is in agreement with the objectives set by the referring inter-disciplinary team; 4. Following assessment, the client is considered to have potential for partial or complete recovery with suitable home rehabilitation within six weeks; 5. The client is able to stand and transfer with one person (with or without the help of a resident carer); 6. The client's home is judged to be safe for the client in addition to the visiting staff and; 7. The client has had a recent acute illness or injury or is at a borderline level of function with an associated reduction in personal (PADL) and / or extended (EADL) activities of daily living and who without input from the team is: I. likely to fail to recuperate full potential of functional recovery; II. or is likely to fail to manage satisfactorily at home despite conventional community support and therefore would be at risk of hospital re-admission or institutionalisation.
排除标准
- •1.Clients who have been discharged from acute hospital care for more than 48 hours
- •2.Clients without clinical need, only social need, e.g. clients needing support during usual caregivers admission to hospital
- •3.Where the home environment is not conducive to achieving the rehabilitation outcomes for the client
- •4.Where the clients primary rehabilitation intervention is provided in an outpatient setting
- •5.Clients with progressive or deteriorating conditions where partial or full recovery cannot be reasonably expected within six weeks (e.g. Palliative care):
- •6.The client is eligible for assessment, treatment and rehabilitation funded under the injury Prevention, Rehabilitation and Compensation Act (2001)
- •7.The clients service needs are covered under another service specification or funding stream
研究者
相似试验
进行中(未招募)
不适用
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. - NDEUCTR2005-005372-32-ITGLAXO SMITHKLINE400
进行中(未招募)
1 期
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen (as lysinate) lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAupper respiratory illness : sore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-008265-36-FRSANOFI-AVENTIS GROUPE835
进行中(未招募)
1 期
The effect of Tiotropium+olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004253-11-GBBoehringer Ingelheim Limited544
进行中(未招募)
不适用
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAEUCTR2008-008265-36-FISANOFI-AVENTIS GROUPE835
进行中(未招募)
不适用
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021778-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG375
